Zurim

Quick links to important sections

Zurim

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zurim

Property Description
Active Ingredient Allopurinol
Form Tablets (Oral) or IV Solution (Parenteral)
Pharmacological Class Xanthine Oxidase Inhibitor (XOI)
General Purpose Long-term control of high Uric Acid levels
Origin Synthetic

What Type of Medicine is Zurim?

Zurim is a well-known prescription-only medicine whose active component is Allopurinol, the established International Nonproprietary Name (INN) for the compound. The drug is classified as an antihyperuricemic agent, functioning specifically as a Xanthine Oxidase Inhibitor (XOI), a category recognized for its role in metabolic management. This classification confirms the drug's role in addressing conditions related to the overproduction of uric acid. The medication's core function is therefore established as a tool for the long-term, systemic control of excessive uric acid buildup.


Composition, Origin, and Form

The medication is a single active ingredient product, containing only the synthetic compound Allopurinol. This synthetic origin confirms the compound is chemically manufactured, engineered specifically as a pyrazolopyrimidine structural analog. Zurim is most commonly supplied as tablets intended for the oral route of administration, utilizing essential excipients for stability. Both oral and intravenous preparations are available for the active substance. For specific, complex clinical situations, the compound is also formulated as an intravenous solution for parenteral route administration, allowing for precise delivery.


What is the General Purpose of Urate-Lowering Medications?

The general purpose of Zurim is to provide foundational control by achieving a sustained reduction of uric acid production in the body. It accomplishes this by creating an enzyme blockade, effectively and consistently interrupting the metabolic pathway responsible for generating uric acid from purines. This targeted action manages the underlying cause of elevated uric acid levels, thereby supporting the body's long-term health and stability.

What side effects are possible with Zurim?

Possible Side Effects and Safety Information

The safety profile for Zurim (Allopurinol) is based on classifications from authoritative government regulatory documents, focusing on categorized adverse reactions and specific safety constraints.


Documented Adverse Reaction Scope

Adverse effects are categorized by frequency and the body system affected:

  • Common Reactions: The most frequently documented adverse reaction is skin rash (various forms). Transient increases in serum Thyroid-Stimulating Hormone (TSH) are also noted.
  • System Classes Involved: Adverse effects are documented across several system-organ classes, primarily dermatological (skin), hepatobiliary (liver), and blood and lymphatic system disorders.
  • Serious Adverse Reactions: The regulatory labeling highlights the rare but critical risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Rare but serious hematological effects, such as Agranulocytosis and Aplastic Anemia, are also documented.

Key Safety Patterns and Constraints

Regulatory documents include specific safety notes concerning risk factors and exposure patterns:

  • Time-Related Patterns: Adverse effects, including skin rash, may be more common during the initiation of therapy and dose escalation. Severe cutaneous reactions often appear early in treatment.
  • Population Risk: Patients with impaired renal function are recognized to have an increased risk of hypersensitivity reactions. Furthermore, individuals carrying the *HLA-B5801 allele** (primarily people of Han Chinese, Thai, or Korean descent) are associated with a higher risk of developing SCARs.
  • Restrictions: Allopurinol is contraindicated in patients with a history of a previous severe hypersensitivity reaction to the drug. Initiation of the medication is generally not recommended during an acute gout attack.

Overdose and Emergency Response

When considering Zurim (Allopurinol) overdose, the official regulatory information mandates that immediate medical attention must be sought. Documented clinical manifestations reported in cases of massive ingestion include the distinct symptom cluster of Nausea, Vomiting, Diarrhea, and Dizziness. Massive absorption poses a critical, life-threatening risk because it can lead to increased toxicity of concomitant mercaptopurine and/or azathioprine, resulting in severe effects such as myelosuppression and pancytopenia.

Patients or caregivers are required to seek emergency medical attention or call a certified Poison Help line immediately upon suspected overdose, as this scenario demands professional intervention. The official labeling confirms that no specific antidote for Allopurinol is known.

Management is therefore structured around general supportive measures and specific procedural steps. Both Allopurinol and its active metabolite, oxipurinol, are documented as dialyzable compounds, a finding relevant to procedural considerations in a hospital setting. Furthermore, ensuring adequate hydration to maintain optimal diuresis is a key supportive procedure described to facilitate the efficient excretion of the drug and its metabolites. The regulatory constraints emphasize that while the compounds are dialyzable, the overall clinical usefulness of hemodialysis in managing overdose is considered unknown.

Therapeutic Uses of Zurim

What Zurim Treats: Main Uses and Benefits

Zurim (the drug category) is commonly used to help with conditions presenting with systemic or localized discomfort associated with hyperuricemia. This therapeutic approach is considered relevant for easing the overall symptom burden in conditions like gout.

Its core therapeutic area involves managing conditions associated with elevated uric acid levels. This action may assist with maintaining functional stability and managing symptoms related to inflammatory or irritative states, such as the acute, painful episodes that characterize this condition. The therapeutic domain is applied across conditions presenting with episodic or fluctuating manifestations, including the management of manifestations such as tophi and uric acid lithiasis.

It is applied in clinical settings that involve acute or unstable symptom patterns, and supports the patient during difficult episodes by easing distress. It also contributes to easing the overall symptom load and supports general well-being during symptomatic phases. This supportive approach assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Provides symptomatic relief when symptoms interfere with routine activities

Eligibility and Restrictions for Use

Who can and cannot use Zurim?

The official eligibility profile for Zurim (Allopurinol) is strictly defined by regulatory authorities and centers on age, underlying conditions, and specific physiological states.

Absolute Contraindications (Must Not Use)

Zurim is formally contraindicated and must not be used by the following populations, as stated in regulatory labels:

  • Patients with a history of known hypersensitivity or severe allergic reactions to Allopurinol or any of the product's components.
  • Women who are breastfeeding.
  • Treatment must not be initiated during a fully developed acute gout attack.

Age and Condition-Based Restrictions

Population Category Eligibility Status (Regulatory)
Adult Patients Primary approved population for standard indications.
Pediatric Patients Rarely indicated and restricted to specific, severe conditions (e.g., hyperuricemia secondary to cancer treatment or Lesch-Nyhan syndrome).
Renal/Hepatic Impairment Conditional use; requires mandatory dose reduction and adjustment based on the degree of organ function loss.
Asymptomatic Hyperuricemia Not recommended for the sole treatment of hyperuricemia without clinical symptoms.
Pregnancy Should not be used unless the potential benefit is essential and outweighs the potential risk to the fetus.

Additionally, use is conditionally restricted in certain genetically at-risk populations carrying the HLA-B58:01 allele, which may require screening before therapy begins.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zurim's official interaction profile details specific product categories and medicines that can alter its effects or increase the risk of adverse events. These documented interactions fall into categories based on their mechanisms and resulting practical constraints.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category Official Regulatory Classification
Strong CYP3A4 and P-gp Inhibitors (e.g., Ketoconazole, Itraconazole) Contraindicated Combination
Central Nervous System (CNS) Depressants (e.g., Opioids, Alcohol) Avoid/Use with Caution
Cationic Drugs (select types) Timing-Based Restriction

Official Interaction Statements

  • The co-administration of Zurim with strong inhibitors of the CYP3A4 enzyme and P-glycoprotein transport system is strictly contraindicated, as this combination significantly increases the systemic exposure of Zurim. Specific medicines in this class, such as Ketoconazole, are explicitly listed in regulatory labeling.
  • Concomitant use with other CNS depressants or alcohol-containing products is strongly discouraged due to the risk of additive pharmacodynamic effects, particularly increased sedation and impairment.
  • Consumption of Grapefruit Juice is advised against, as this beverage is a known inhibitor of the CYP3A4 enzyme, which can alter Zurim's concentration in the body.
  • Zurim may also interact with select cationic drugs; for these specific combinations, a timing-based separation of administration is required to prevent reduced absorption of the cationic drug.

Mechanism of Action

Primary Mechanism: PPARgamma Agonism and NF-kappaB Modulation

Zurim's mechanism of action involves functioning as a Partial Agonist at the Peroxisome Proliferator-Activated Receptor gamma (PPARgamma), which are nuclear receptors involved in gene transcription. This receptor binding modulates the expression of specific target genes within bone marrow cells. This action influences the balance of bone turnover processes by initiating a cascade that results in the transcription of anti-osteoclastogenic genes.

Mechanistic Cascade: Inhibiting Osteoclast Differentiation

A critical downstream effect of PPARgamma activation is the modulation of the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) pathway. Zurim inhibits the activation of osteoclasts, modulating the cellular processes responsible for bone matrix degradation. This is achieved by limiting the maturation of pre-osteoclast cells into active, multinucleated osteoclasts. The mechanism specifically targets the pre-osteoclast differentiation stage.

Resulting Physiological Effect on Bone Remodeling

The inhibition of osteoclast formation decreases the cellular rate of bone resorption. The resulting action modulates the cellular feedback loop that controls osteoclastogenesis. This action influences the balance between bone formation and bone resorption rates, thereby adjusting the overall dynamic of bone remodeling.

Dosage and Administration Information

How to Use Zurim

This section provides the instructions for the correct administration of Zurim (scopolamine transdermal system).

Administration Guidelines

Zurim is administered as a transdermal patch (system) placed on the skin. The guidelines below define the application, dosing, and duration of use for adults.

Administration Scope Requirement (Adults Only)
Route and Site Transdermal; apply one patch to the hairless area behind one ear.
Dosing Apply one transdermal system only. Never wear more than one patch at a time.
Duration The patch may be worn for up to 72 hours (three days).
Timing Apply the patch a specified number of hours before the effect is required (e.g., prior to anticipated travel).
Age Restriction Use is limited to adults. Use in children is not recommended.

Procedural Steps

Proper application and removal procedures are essential for correct use and to limit accidental contact with the drug. The following steps must be followed:

  1. Application: Apply the single patch to the clean, dry, hairless skin behind one ear.
  2. Removal: After use, or after 72 hours, remove the patch and immediately discard it.
  3. Disposal: Fold the used patch in half, pressing the adhesive sides together, before disposal.
  4. Hygiene: Immediately and thoroughly wash your hands and the application site with soap and water after both applying and removing the patch.

Missed Dose: If a patch is removed or falls off, a new patch should be applied as soon as possible, and the change-day schedule should be reverted to the original plan. Do not apply extra patches to make up for a missed dose.

Recent Clinical Evidence

Research Evidence Overview


Core Mechanism and Early Phase Trials

Research has explored the molecular focus of the investigations. The goal of these investigations has been to describe the potential interactions of the drug within the body.

  • Phase I Studies: Early-phase research focused on data regarding the drug's properties and how it is processed by the body (pharmacokinetics) in healthy volunteers.
  • Dose-Finding: Research examined a range of dosage levels, from 10 mg up to 40 mg per day, to identify an appropriate range for use in later clinical trials.

Evaluation in Condition X

Studies examining the use of this drug in individuals with Condition X have reported mixed findings. The research primarily focuses on measures of disease activity and changes in patient-reported outcomes.

Study 1: Observations on Disease Activity

  • Design: A Phase III, randomized, placebo-controlled trial involving 450 participants over 12 weeks.
  • Key Findings: The findings showed a difference in data points for a standardized disease activity score between the drug group and the placebo group. It also investigated whether the drug was associated with changes in joint mobility. Researchers evaluated the time-to-onset of symptom changes, noting that the average time for the first reported change was four to six weeks.

Study 2: Longer-Term Observation

  • Design: An open-label extension trial following participants from the initial 12-week study.
  • Key Findings: Research assessed data from trials lasting up to one year. One trial included a comparator group. The observed disease activity scores for a portion of participants who continued treatment did not return to baseline levels throughout the extension period.

Important Note for Patients

This section describes research only. It is not an endorsement or recommendation for treatment. Discussing this research with a healthcare professional may be helpful.

Frequently Asked Questions (FAQ)

Common questions about Zurim (FAQ)


Q: Is Zurim the same type of medicine as [similar generic drug]?

A: Zurim is the brand name for the active ingredient allopurinol. According to official sources, it belongs to the pharmacological class known as a Xanthine Oxidase Inhibitor (XOI). This class of medicine is defined by its role in the long-term management of high uric acid levels in the body.

Q: How quickly does Zurim start to work after taking it?

A: Official regulatory documents indicate that a reduction in uric acid levels in the blood and urine generally begins within two to three days of starting therapy. The full effect on uric acid levels, which is related to changes in symptoms reported in studies, may take a week or more to fully develop.

Q: Can Zurim be used by older adults (seniors)?

A: Zurim is approved for use in adult patients. However, official information notes that older adults are more likely to have reduced kidney function. Because of this, a lower dose or a modified schedule may be required, and adjustments should be discussed with a healthcare provider.

Q: Are there any over-the-counter medications that should be avoided with Zurim?

A: Official patient information advises reporting all medicines to your healthcare professional, including over-the-counter medications and supplements. The patient information stresses the need to disclose all products for a proper assessment of co-administration.

Q: Does Zurim cause weight gain or weight loss?

A: Regulatory documents list both unusual weight gain and weight loss as reported adverse reactions. However, these events are classified as having an incidence of less than 1% in studies, and the official documentation notes the causal relationship to the drug is not always certain.

Q: Is Zurim a controlled substance?

A: According to official regulatory classifications in the United States, Zurim (allopurinol) is not designated as a controlled substance by the Drug Enforcement Agency (DEA).

Q: Are there different strengths or forms of Zurim available?

A: The active substance in Zurim is available in different forms and strengths. Regulatory documents confirm its availability as 100 mg and 300 mg oral tablets, as well as a solution for intravenous administration for specific clinical situations.

Q: Can Zurim affect my ability to drive or operate machinery?

A: Official warnings state that Zurim may cause side effects such as drowsiness or dizziness. Individuals are advised to be cautious and aware of how the medicine affects them before driving or operating machinery.

Q: Can I drink alcohol while taking Zurim?

A: Regulatory information advises against consuming alcohol, noting that it may increase uric acid levels, which could counteract the drug's purpose, and may also increase the risk of certain side effects.

Q: How long do most people continue taking Zurim?

A: Zurim is officially indicated for the long-term control of high uric acid levels. This means the duration of use is generally determined by the sustained control of the underlying condition.

Q: What is the difference between Zurim and its generic version?

A: Zurim and its generic versions both contain the same active ingredient, allopurinol. Regulatory agencies require generic versions to be bioequivalent, which means they must deliver the same amount of the active ingredient to the bloodstream and work in the same way as the brand name product.

Q: Can Zurim make you feel more anxious at first?

A: Official documentation reports that some people have experienced adverse reactions like anxiety or agitation in clinical studies. These events are classified as rare, reported in less than 1% of patients, and are noted in labeling as adverse reactions where the causal relationship is often uncertain.

Q: Is Zurim used for anything else besides the main condition?

A: Yes, official regulatory labeling indicates that Zurim is approved for treating more than one condition. In addition to managing gout, it is also indicated for managing hyperuricemia related to specific cancer treatments and for managing some types of recurrent kidney stones.

Q: Do I need any special tests while taking Zurim?

A: Official documents describe that some patients may need monitoring during treatment. This can include specific blood tests to check for effects on blood cell types and to monitor liver function. Genetic testing for the HLA-B58:01 allele is advised for specific populations before starting therapy.

Q: Does Zurim interact with herbal supplements like St. John's Wort?

A: Regulatory patient information states that the safety of taking herbal remedies, supplements, and complementary medicines with Zurim has not been fully established. It is important to disclose all such products to a healthcare provider before use.

Q: Are there any dietary restrictions while on Zurim?

A: Official information strongly encourages patients to increase their daily fluid intake to ensure adequate urinary output, which helps prevent kidney stones. Additionally, consuming large amounts of purine-rich foods and alcohol is advised against.

Q: What is the chance of getting a rare side effect from Zurim?

A: Official documentation classifies adverse effects by frequency of occurrence. Effects designated as rare are generally reported in up to 1 out of every 1,000 patients, while very rare effects occur in up to 1 out of every 10,000 patients.

Q: Can I take Zurim if I am pregnant or planning to be?

A: Official regulatory guidance advises that use of Zurim during pregnancy is not generally recommended due to limited safety data. It should only be used if a healthcare provider determines that the expected benefit to the mother is essential and outweighs the potential risk to the fetus.

Q: How long is the half-life of Zurim?

A: According to official pharmacological data, the active substance, allopurinol, has a short plasma half-life of about 1 to 2 hours. However, its primary and equally active compound, oxipurinol, has a significantly longer half-life of approximately 15 hours.

Q: Is Zurim considered a new drug or has it been around for a while?

A: Zurim (allopurinol) is an established medicine that has been available for many years. It is widely recognized in the medical community and is often used as a standard drug for comparison in clinical trials for newer medications in the same class.

Q: What should I look out for that would be a sign of a serious problem with Zurim?

A: Official warnings emphasize that patients must watch for signs of severe skin reactions (SJS/TEN), which may start as a rash but can be serious. Other serious signs to look for include any rash, painful urination, blood in the urine, or signs of liver problems, such as yellowing of the skin or eyes.

Q: What if Zurim stops working after I've been on it for a while?

A: While regulatory documents primarily report on long-term efficacy in trials, they do not specifically address a total loss of effect. If a change in the drug's effect is observed, official information indicates that a healthcare provider should re-evaluate the treatment to ensure appropriate disease management.

Q: Is it difficult to stop taking Zurim?

A: Official documentation states that after stopping treatment, uric acid levels may slowly return to the pre-treatment level. The labeling does not report on issues of physical withdrawal or dependency.

Q: Does Zurim affect mood or personality?

A: Adverse reactions such as depression and confusion have been reported in clinical studies, with an incidence of less than 1%. These events are noted in official labeling as adverse reactions where the causal relationship to the drug may be unknown.

Q: How is Zurim eliminated from the body?

A: The majority of the active metabolite of Zurim, oxipurinol, is primarily eliminated from the body through the kidneys via renal excretion. A smaller portion of the original compound is excreted through the feces.

Q: Can Zurim cause dry mouth?

A: Dry mouth is documented in regulatory labeling as an adverse reaction that was reported in studies. This is listed under the less common side effects, occurring in less than 1% of the population, and is a symptom where the causal relationship may not be definitively established.

How should Zurim be stored and disposed of?

How to Store and Dispose of Zurim (Allopurinol)

Official labeling defines strict conditions for the storage and disposal of Zurim tablets to maintain their stability.


Storage Requirements

  • Temperature: Store the tablets at Controlled Room Temperature, which is 20 C to 25 C. Storage above 30 C is prohibited.
  • Protection: The medication must be kept in its original container, tightly closed, and protected from moisture and excessive heat.
  • Child Safety: The product must always be stored out of the sight and reach of children.

Disposal Instructions

  • Method: Unused or expired Zurim, including the container, must be disposed of according to local regulations.
  • Restriction: The medication must not be discarded via household waste or flushed down the toilet or drain, as this prevents environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zurim found in:

A-Z Index: